Medical countermeasures to protect humans from anthrax bioterrorism

Trends in Microbiology

Volumn 17, Issue 11, 2009, Pages 522-528

  Bouzianas, Dimitrios G ^a  

^a ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABTHRAX; AMOXICILLIN; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTITOXIN; BACTERIAL ANTIGEN; CIPROFLOXACIN; DOXYCYCLINE; ETI 204; LIVE VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY W1; MONOCLONAL ANTIBODY W2; PENICILLIN G; RAXIBACUMAB; RPA 102; UNCLASSIFIED DRUG;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; BACILLUS ANTHRACIS; BACTERIAL GENOME; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BIOLOGICAL WARFARE; BIOLOGICAL WARFARE AGENT; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE REACTION; MASS IMMUNIZATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SPORE GERMINATION; VACCINE PRODUCTION;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; ANTITOXINS; BIOTERRORISM; HISTORY, 21ST CENTURY; HUMANS; MODELS, BIOLOGICAL; UNITED STATES;

BACILLUS ANTHRACIS;

EID: 70350292553     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2009.08.006     Document Type: Review

References (76)

1. US Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID), Biodefense Research Agenda for CDC Category A Agents: 2006 Progress Report, pp. 15-23.
2. Inglesby T.V., et al., for the Working Group on Civilian Biodefense. Anthrax as a biological weapon - updated recommendations for management. J. Am. Med. Assoc. 287 (2002) 2236-2252
3. Wang J.Y., and Roehler M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol. 4 (2005) 4-11
4. Webb G. Being Prepared: Modeling the Response to an Anthrax Attack. Ann. Intern. Med. 142 (2005) 667-668
5. Wills B., et al. Analysis of suspicious powders following the post 9/11 anthrax scare. J. Med. Toxicol. 4 (2008) 93-95
6. Riedel S. Anthrax: a continuing concern in the era of bioterrorism. BUMC Proc. 18 (2005) 234-243
7. Meselson M., et al. The Sverdlovsk anthrax outbreak of 1979. Science 266 (1994) 1202-1208
8. World Health Organization. Health Aspects of Chemical and Biological Weapons (1970), World Health Organization
9. Office of Technology Assessment, US Congress (1993) Proliferation of Weapons of Mass Destruction, pp. 53-55, US Government Printing Office
10. Bouzianas D.G. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Expert Rev. Anti-infect. Ther. 5 (2007) 665-684
11. Henriques A.O., and Moran C.P. Structure, assembly, and function of the spore surface layers. Annu. Rev. Microbiol. 61 (2007) 555-588
12. Daubenspeck J.M., et al. Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium. J. Biol. Chem. 279 (2004) 30945-30953
13. Read T.D., et al. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 423 (2003) 81-86
14. Cote C.K., et al. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect. Immun. 74 (2006) 469-480
15. Cleret A., et al. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178 (2007) 7994-8001
16. Dixon T.C., et al. Anthrax. N. Engl. J. Med 341 (1999) 815-826
17. Sherer K., et al. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am. J. Respir. Crit. Care Med. 175 (2007) 211-221
18. Warfel J.M., et al. Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. 166 (2005) 1871-1881
19. Baldari C.T., et al. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 27 (2006) 434-440
20. Baillie L.W. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 101 (2006) 594-606
21. Brey R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 57 (2005) 1266-1292
22. Zaric G.S., et al. Modeling the logistics of response to anthrax bioterrorism. Med. Decis. Making. 28 (2008) 332-350
23. Grabenstein J.D. Countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46 (2008) 129-136
24. Weiss M.M., et al. Anthrax vaccine and public health policy. Am. J. Public Health 97 (2007) 1945-1951
25. Kubler-Kielb J., et al. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-γ-D-glutamic acid-protein conjugates. Infect. Immun. 74 (2006) 4744-4749
26. Joyce J., et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-γ-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J. Biol. Chem. 281 (2006) 4831-4843
27. Rhie G.E., et al. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl Acad. Sci. U. S. A. 100 (2003) 10925-10930
28. Pittman P.R., et al. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24 (2006) 3654-3660
29. Hewetson J.F., et al. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 26 (2008) 4262-4266
30. Marano N., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. J. Am. Med. Assoc 300 (2008) 1532-1543
31. Wasserman G.M., et al. Analysis of adverse events after anthrax immunization in US army medical personnel. J. Occup. Environ. Med. 4 (2003) 222-233
32. Keitel W.A. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine. Expert Rev. Vaccines 5 (2006) 417-430
33. Hepler R.W., et al. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 24 (2006) 1501-1514
34. Gorse G.J., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24 (2006) 5950-5959
35. Williamson E.D., et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73 (2005) 5978-5987
36. Duc le H., et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 25 (2007) 346-355
37. Park Y.S., et al. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 76 (2008) 1952-1959
38. Jiang G., et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J. Pharm. Sci. 95 (2006) 80-96
39. Kenney R.T., et al. Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis. 190 (2004) 774-782
40. Stokes M.G., et al. Oral administration of a Salmonella-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect. Immun. 75 (2007) 1827-1834
41. Smith M.E.S., et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353 (2006) 344-356
42. Streatfield S.J. Engineered chloroplasts as vaccine factories to combat bioterrorism. Trends Biotechnol. 24 (2006) 339-342
43. Liu T.H., et al. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors. Mol. Ther. 17 (2008) 373-379
44. McConnell M.J., et al. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol. Ther. 15 (2007) 203-210
45. Cote C.K., et al. Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization. Microbiology 154 (2008) 619-632
46. Scorpio A., et al. Treatment of experimental anthrax with recombinant capsule depolymerase. Antimicrob. Agents Chemother. 52 (2008) 1014-1020
47. Mosser E.M., and Rest R.F. The Bacillus anthracis cholesterol-dependent cytolysin, anthrolysin O, kills human neutrophils, monocytes and macrophages. BMC Microbiol. 6 (2006) 56
48. Chitlaru T., et al. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect. Immun. 75 (2007) 2841-2852
49. Albrecht M.T., et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun. 75 (2007) 5425-5433
50. Hull A.K., et al. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine 23 (2005) 2082-2086
51. Phipps A.J., et al. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol. Mol. Biol. Rev. 68 (2004) 617-629
52. Rossi C.A., et al. Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax. Infect. Immun. 76 (2008) 5790-5801
53. Kozel T.R., et al. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect. Immun. 75 (2007) 152-163
54. Mohamed N., et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73 (2005) 795-802
55. Chen Z., et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 193 (2006) 625-633
56. Subramanian G.M., et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen in healthy volunteers. Clin. Infect. Dis. 41 (2005) 12-20
57. Holty J.E., et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann. Intern. Med. 144 (2006) 270-280
58. Turk B.E. Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Curr. Pharm. Biotechnol. 9 (2008) 24-33
59. Hanna M.L., et al. Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor. Bioorg. Chem. 35 (2007) 50-58
60. Brookmeyer R., et al. Public health vaccination policies for containing an anthrax outbreak. Nature 432 (2004) 901-904
61. Bryskier A. Bacillus anthracis and antibacterial agents. Clin. Microbiol. Infect. 8 (2002) 467-478
62. Clatworthy A.E., et al. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3 (2007) 541-548
63. Pezard C., et al. Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59 (1991) 3472-3477
64. Dalkas G.A., et al. Low molecular weight inhibitors of the protease anthrax lethal factor. Mini. Rev. Med. Chem. 8 (2008) 290-306
65. Verma R.P., and Hansch C. Combating the threat of anthrax: a quantitative structure-activity relationship approach. Mol. Pharm. 5 (2008) 745-759
66. Schepetkin I.A., et al. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J. Med. Chem. 49 (2006) 5232-5244
67. Johnson S.L., et al. A high-throughput screening approach to anthrax lethal factor inhibition. Bioorg. Chem. 35 (2007) 306-312
68. Johnson S.L., et al. Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem. Biol. Drug. Des. 71 (2008) 131-139
69. Cui X., et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J. Infect. Dis. 195 (2007) 572-580
70. Vietri N.J., et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7813-7816
71. Shepard C.W., et al., CDC Adverse Events Working Group. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg. Infect. Dis. 8 (2002) 1124-1132
72. Fowler R.A., et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann. Intern. Med. 142 (2005) 601-610
73. Stearns-Kurosawa D.J., et al. Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am. J. Pathol. 169 (2006) 433-444
74. Hahn U.K., et al. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24 (2006) 4569-4571
75. Young J.T., Collier R.J., et al. Anthrax toxin: receptor binding, internalization, pore formation and translocation. Annu. Rev. Biochem. 76 (2007) 243-265
76. Barth H., et al. Binary bacterial toxins: biochemistry, biology and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev. 68 (2004) 373-402